|
May 9
|
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
|
|
May 8
|
Avidity Biosciences to Participate in Upcoming Investor Conference
|
|
May 8
|
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
|
|
Apr 4
|
Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
|
|
Mar 15
|
Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
|
|
Mar 4
|
Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy
|
|
Mar 4
|
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
|
|
Mar 1
|
Avidity Biosciences Full Year 2023 Earnings: Misses Expectations
|
|
Feb 29
|
Avidity Biosciences Honors Rare Disease Day®
|
|
Feb 29
|
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
|
|
Feb 28
|
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 28
|
Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress
|
|
Feb 28
|
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
|
|
Feb 27
|
Avidity Biosciences to Participate in Upcoming Investor Conferences
|
|
Dec 21
|
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
|
|
Nov 30
|
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
|
|
Nov 29
|
Company News for Nov 29, 2023
|
|
Nov 29
|
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
|